New study aims to beat stomach cancer without surgery
NCT ID NCT07290985
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study tests a personalized treatment for stomach or esophageal cancer. Doctors will use tumor markers to pick the best mix of chemotherapy, immunotherapy, and targeted drugs. The goal is to shrink the cancer so much that some patients may avoid surgery entirely. About 121 adults with early-stage but high-risk cancer will join this two-stage trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can switching cancer therapy early extend life in stomach cancer?
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers
- New combo aims to keep stomach cancer at bay longer
- New cancer drug HH160 enters first human tests for advanced tumors
- Could a $4 statin improve cancer survival?
- Supercharged t cells take on Hard-to-Treat cancers